Table 4.
Odds ratios (OR), 95% CI of the associations between serum biomarkers and percent of sites with PPD ≥ 4 mm or percent of sites with CAL ≥ 4 mm.
| Low vs. Medium/High Percent of Sites with PPD ≥ 4 mm | ||||
|---|---|---|---|---|
| Biomarker (pg/mL) | Crude OR (95% CI) | p-Value | Adjusted OR (95% CI) ‡ | p-Value |
| IL-1b | 1.08 (0.97–1.21) | 0.154 | 1.09 (0.97–1.24) | 0.155 |
| IL-6 | 1.03 (0.97–1.10) | 0.357 | 1.04 (0.96–1.13) | 0.364 |
| IL-10 | 1.09 (1.01–1.17) | 0.028 | 1.10 (1.01–1.20) | 0.033 |
| TNF-a | 1.03 (0.98–1.09) | 0.228 | 1.03 (0.97–1.09) | 0.384 |
| sICAM-1 † | 1.01 (1.00–1.01) | 0.074 | 1.01 (1.00–1.02) | 0.060 |
| sVCAM-1 † | 1.00 (0.99–1.01) | 0. 699 | 1.00 (0.99–1.01) | 0.798 |
| RANKL | 1.00 (0.99–1.00) | 0.440 | 1.00 (0.99–1.00) | 0.376 |
| Low vs. Medium/High Percent of Sites with CAL ≥ 4 mm | ||||
| Biomarker (pg/mL) | ||||
| IL-1b | 1.07 (0.95–1.19) | 0.251 | 1.08 (0.95–1.23) | 0.252 |
| IL-6 | 1.00 (0.96–1.04) | 0.994 | 0.99 (0.95–1.04) | 0.668 |
| IL-10 | 1.08 (1.00–1.17) | 0.038 | 1.06 (0.98–1.16) | 0.152 |
| TNF-a | 1.04 (0.98–1.10) | 0.170 | 1.01 (0.95–1.08) | 0.665 |
| sICAM-1 † | 1.00 (1.00–1.01) | 0.186 | 1.00 (1.00–1.01) | 0.286 |
| sVCAM-1 † | 1.00 (0.99–1.01) | 0.672 | 1.00 (0.99–1.00) | 0.338 |
| RANKL | 1.01 (0.99–1.03) | 0.281 | 1.01 (0.99–1.04) | 0.256 |
† value/104; ‡ adjusted for age, gender, education, smoking and alcohol status, BMI, mean plaque index, lipid-lowering agents (LLA) use, and HbA1c. p-values in bolds are statistically significant (p < 0.05) or close to being significant (p < 0.10).